Earnings quality remains high with an OCF/NI ratio of 1.48, though free cash flow margins have contracted to 10.9% amid aggressive $496.7 million share repurchases.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Cash from Operations | 615.22M | 654.33M | 673.55M | 459.45M | 715.26M | 639M | 492.27M | 330.84M | 359.5M | 286.78M | 341.6M | 317.5M | 287.96M | 258.96M | 244.88M | 244.78M | 250.75M | 217M | 173M | 84.81M | 101.48M | 91.24M | 53.8M | 64.06M | 36.69M | 58.09M | 38.87M | 26.18M | 11.6M | 8.5M | 4.1M |
| Operating CF Margin % | - | 31.31% | 34.05% | 23.38% | 33.4% | 28.38% | 26.32% | 21.67% | 23.94% | 20.23% | 25.53% | 24.79% | 21.41% | 19.89% | 19.52% | 20.93% | 23.06% | 21.49% | 19.37% | 13.05% | 21.79% | 22.9% | 14.13% | 18.23% | 12.29% | 22.02% | 19.05% | 18.18% | 10.53% | 11.44% | 7.56% |
| Operating CF Growth % | -42.36% | -2.85% | 46.6% | -35.76% | 11.93% | 29.81% | 48.79% | -7.97% | 25.36% | -16.05% | 7.59% | 10.26% | 11.2% | 5.75% | 0.04% | -2.38% | 15.56% | 25.43% | 103.98% | -16.43% | 11.23% | 69.59% | -16.02% | 74.62% | -36.84% | 49.43% | 48.5% | 125.66% | 36.47% | 107.32% | 5.13% |
| Net Income | 402.17M | 424.88M | 83.59M | 341.3M | 423.21M | 512.6M | 73.64M | -41.45M | 190.38M | 40.39M | 80.3M | 126.86M | 117.2M | 69.1M | 129.54M | 94.95M | 144.31M | 137.77M | 89.03M | 50.12M | 70.54M | 62.23M | 48.7M | 42.85M | 23.14M | 34.42M | 20.11M | 12.62M | 12.4M | 8.8M | 5.3M |
| Depreciation & Amortization | 202.28M | 193.75M | 203.27M | 205.34M | 208.4M | 214.93M | 209.97M | 231.46M | 206.44M | 216.45M | 213.06M | 191.47M | 200.78M | 199.35M | 197.89M | 167.38M | 142.78M | 120.39M | 105.7M | 62.58M | 30.04M | 24.95M | 22.96M | 25.79M | 24.71M | 15.06M | 10.46M | 7.83M | 5.8M | 4.9M | 2.5M |
| Stock-Based Compensation | 47.71M | 50.4M | 43.63M | 47.1M | 49.51M | 38.39M | 40.94M | 65.89M | 40.11M | 34.44M | 28.29M | 27.57M | 42.19M | 37.94M | 25.36M | 19.54M | 13.59M | 9.75M | 9.79M | 8.98B | 326M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | -23M | -20.07M | -23.04M | 10.73M | -9.6M | -5.29M | -14.26M | -55.36M | -23.27M | 39.55M | -65.97M | -37.19M | -41.29M | -68.09M | -22.77M | -31.86M | -19.94M | -10.61M | -17.69M | -1.65M | 5.21M | -2.2M | -10.47M | 12.18M | 5.03M | -1.79M | -5.38M | -1.53M | -1M | -900K | 400K |
| Other Non-Cash Items | 48.11M | 39.88M | 230.65M | 41.94M | 75.63M | 8.38M | 165.18M | 174.63M | 41M | 23.18M | 75.64M | 89.91M | 47.89M | 14.99M | -1.27M | 37.69M | -14.09M | -5.51M | 4.24M | -8.95B | -325.23M | 10.01M | 12.62M | 8.38M | -1.88M | 16.25M | 25.66M | 6.24M | 100K | 400K | 100K |
| Working Capital Changes | -62.05M | -34.51M | 135.45M | -186.96M | -31.88M | -130.01M | 16.8M | -44.32M | -95.16M | -67.23M | 10.29M | -81.11M | -78.81M | 5.67M | -83.87M | -42.92M | -15.9M | -34.8M | -18.07M | -55.83M | -5.08M | -3.75M | -20.01M | -25.14M | -14.31M | -5.85M | -11.97M | 1.02M | -6.3M | -4.7M | -4.2M |
| Change in Receivables | -45.06M | -36.39M | 12.22M | -55.12M | 15.45M | -7.4M | -14.71M | -39.58M | -41.81M | -34.16M | -12.24M | -24.76M | -16.56M | -14.92M | -14.29M | -28.2M | -6.88M | -25.21M | -19.08M | 1.81B | 378M | 54M | 128M | 1.75B | 631M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | -20.19M | -848K | 87.75M | -44.79M | -61.95M | -81.8M | -107.57M | -30.03M | -36.92M | -21.63M | -20.35M | -33.19M | -41.79M | -17.5M | -20.38M | -15.95M | 2.35M | -21.53M | -30.37M | -8.74M | -4.2M | 3.76M | 2.02M | -6.4M | -18.18M | -3.93M | -6.59M | -3.7M | -3.2M | -6M | -4.2M |
| Change in Payables | 5.26M | -8.42M | 1.45M | -22.42M | -1.76M | -5.97M | 8.44M | 9.25M | 6.99M | 4.32M | -1.47M | 7.73M | -5.5M | -6.79M | -9.95M | 7.26M | 3.48M | -9.08M | 5.75M | 956M | 2.72B | -4.71B | 599M | -6.61B | -424M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -213.89M | -305.28M | -249.23M | -87.66M | -726.76M | -202.43M | -453.29M | -222.28M | -211.36M | -464.26M | -179.06M | -146.2M | -407.6M | -251.74M | -300.89M | -540.32M | -215.51M | -341.74M | -210.52M | -659.67M | -165.47M | -98.5M | -51.15M | -14.06M | -64.79M | -90.8M | -45.03M | -23.73M | -11.7M | -5.9M | -38.3M |
| Capital Expenditures | -210.7M | -207.13M | -167.17M | -162.8M | -149.34M | -206.53M | -304.24M | -274.88M | -150.76M | -124.41M | -93.92M | -117.48M | -97M | -118.69M | -128.09M | -121.39M | -123.91M | -69.36M | -57.92M | -58.61M | -35.35M | -13.73M | -12.62M | -19.56M | -59.14M | -102.07M | -39.45M | -11.81M | -10.5M | -6.8M | -9.7M |
| CapEx % of Revenue | 10.04% | 9.91% | 8.45% | 8.28% | 6.97% | 9.17% | 16.27% | 18.01% | 10.04% | 8.78% | 7.02% | 9.17% | 7.21% | 9.12% | 10.21% | 10.38% | 11.39% | 6.87% | 6.49% | 9.02% | 7.59% | 3.45% | 3.32% | 5.57% | 19.8% | 38.7% | 19.33% | 8.2% | 9.53% | 9.15% | 17.9% |
| Acquisitions | -224.63M | -291.23M | 0 | -149.53M | -63.65M | -16.63M | -239.57M | -67.06M | -172.83M | -50.55M | -90.49M | -66.93M | -160.44M | -170.55M | -132M | -457.48M | -36.98M | -234.73M | -150.53M | -859.69M | -95.38M | -82M | 17.67M | 1.79M | -14.06M | 274K | 385K | 98K | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -135.34M | -32.16M | 21.35M | -66.55M | -9.77M | 61.47M | -66.57M | 22.7M | -2.13M | -22.98M | -8.74M | -5.88M | 3.64M | -977K | 1.31M | 2.02M | 3.47M | 869K | -208K | 5.82M | 1.91M | -17.76M | -33.1M | -2.78M | -2.37M | -2.32M | -817K | -32K | -2.6M | -1M | -500K |
| Cash from Financing | -395.93M | -178.98M | -422.9M | -433.83M | -125.8M | -150.37M | -74.32M | -639.08M | 360.41M | 387.19M | -10.6M | -258.61M | 192.84M | -68.76M | 226.6M | -310.63M | -35.23M | 629.2M | 12.77M | 494.05M | 303.16M | 2.96M | 95.62M | -1.88M | 6.12M | 66.25M | 14.84M | 3.6M | 1.8M | 3.2M | 31.9M |
| Debt Issued (Net) | 208.15M | 208.15M | -107.33M | -436.76M | -108.55M | -41.34M | -35.55M | -505.43M | 493.57M | 722.86M | -8.06M | -252.95M | 325.34M | -6.49M | 249.22M | -429.56M | -50.25M | -27.99M | -5M | 440.23M | 284.45M | -5.46M | 90.49M | -4M | 3.79M | 58.56M | -5.92M | 1.72M | 714K | 2.5M | 800K |
| Equity Issued (Net) | -519.08M | -307.36M | -292.1M | -17.68M | -25.36M | -92.07M | -77.84M | -72.38M | -104.69M | -304.92M | 6.27M | -10.5M | -126.89M | -60.69M | -35.65M | 0 | 11.24M | 650.49M | 18.45M | 42.28M | 11.01M | 7.96M | 5.13M | 2.11M | 2.33M | 4.09M | 20.76M | 2.68M | 939K | 700K | 31.1M |
| Dividends Paid | -54.24M | -54.24M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -519.08M | -307.36M | -292.1M | -17.68M | -25.36M | -99.99M | -63.99M | -74.45M | -104.69M | -60.97M | 0 | -20.82M | -126.89M | -86.03M | -35.65M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -30.76M | -25.53M | -23.47M | 20.61M | 8.11M | -16.95M | 39.07M | -61.28M | -28.48M | -30.76M | -8.81M | 4.84M | -5.61M | -129K | 13.04M | -2.39M | 3.78M | 6.7M | -686K | 11.54M | 7.7M | 455K | 0 | 0 | 0 | 3.6M | 0 | -803K | 147K | 0 | 0 |
| Net Change in Cash | 7.53M | 175.45M | -4.53M | -62.59M | -149.85M | 282.53M | -31.23M | -529.69M | 501.37M | 218.53M | 149.17M | -102.66M | 62.36M | -63.73M | 172.9M | -607.27M | 2.85M | 492.24M | -14.01M | -83.04M | 238.66M | -4.67M | 97.38M | 54.1M | -11.57M | 32.45M | 9.14M | 5.8M | 2M | 2.3M | -3.3M |
| Free Cash Flow | 410.54M | 453.28M | 506.38M | 296.65M | 565.93M | 432.47M | 188.03M | 55.96M | 208.73M | 162.37M | 247.68M | 200.02M | 190.96M | 140.26M | 116.8M | 123.39M | 126.84M | 147.64M | 115.08M | 26.2M | 66.13M | 77.51M | 41.18M | 44.5M | -22.45M | -43.98M | -573K | 14.37M | 1.1M | 1.7M | -5.6M |
| FCF Margin % | 19.56% | 21.69% | 25.6% | 15.09% | 26.43% | 19.21% | 10.05% | 3.67% | 13.9% | 11.45% | 18.51% | 15.61% | 14.2% | 10.77% | 9.31% | 10.55% | 11.66% | 14.62% | 12.89% | 4.03% | 14.2% | 19.46% | 10.82% | 12.66% | -7.52% | -16.67% | -0.28% | 9.98% | 1% | 2.29% | -10.33% |
| FCF Growth % | -18.45% | -10.49% | 70.7% | -47.58% | 30.86% | 129.99% | 236.02% | -73.19% | 28.55% | -34.44% | 23.83% | 4.74% | 36.14% | 20.09% | -5.35% | -2.72% | -14.09% | 28.29% | 339.29% | -60.38% | -14.69% | 88.23% | -7.47% | 298.23% | 48.95% | -7575.39% | -103.99% | 1205.91% | -35.29% | 130.36% | -354.55% |
| FCF per Share | 1.96 | 2.18 | 2.32 | 1.36 | 2.54 | 1.92 | 0.83 | 0.25 | 0.89 | 0.70 | 1.08 | 0.88 | 0.82 | 0.60 | 0.50 | 0.54 | 0.55 | 0.72 | 0.59 | 0.15 | 0.45 | 0.54 | 0.29 | 0.31 | -0.16 | -0.31 | -0.00 | 0.11 | 0.01 | 0.01 | -0.05 |
| FCF Conversion (FCF/Net Income) | 1.02x | 1.54x | 8.06x | 1.35x | 1.69x | 1.25x | 1.37x | -7.98x | 1.89x | 7.10x | 4.25x | 2.44x | 2.47x | 3.75x | 1.89x | 2.55x | 1.74x | 1.58x | 1.94x | 1.69x | 1.44x | 1.47x | 1.10x | 1.49x | 1.59x | 1.69x | 1.85x | 1.88x | 0.88x | 0.97x | 0.77x |
| Interest Paid | 0 | 0 | 24.18M | 20.35M | 23.21M | 21.59M | 25.35M | 29.72M | 25.9M | 20.25M | 18.23M | 20.8M | 24.05M | 31M | 17.3M | 20.76M | 25.56M | 27.66M | 36.46M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 15.68M | 82.41M | 120.48M | 102.08M | 42.57M | 41.47M | 29.32M | 40.5M | 22.67M | 34.44M | 12.54M | 14.52M | 61.59M | 41.49M | 33.78M | 36M | 39.48M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Diagnostic market share erosion
According to recent financial disclosures, QIAGEN consistently generates operating cash flow significantly in excess of net income, with the OCF/NI ratio reaching 1.48 in 2026Q1, suggesting that the company's reported earnings are supported by robust cash generation despite ongoing volatility in bottom-line accounting metrics.
The persistent gap between net income and operating cash flow indicates that non-cash charges, such as amortization of acquired intangibles, continue to depress reported earnings while cash-generative operations remain intact. Investors should monitor this divergence as it confirms that the core business model remains highly cash-productive even when accounting-based net income appears suppressed.
As reported in quarterly statements, QIAGEN's free cash flow margin has trended downward to 10.9% in 2026Q1, a notable contraction from the 27.5% peak observed in 2024Q3, reflecting a combination of moderating cash inflows and sustained capital intensity required to support the company's five growth pillars.
This trajectory suggests that the company is entering a phase where capital requirements are rising relative to cash generation, potentially limiting the flexibility of its capital allocation strategy. The decline in FCF margins warrants further investigation into whether this is a temporary investment cycle or a structural shift in the cost of maintaining its diagnostic platform.
Based on the provided financial data, QIAGEN's capital expenditure as a percentage of revenue reached 9.8% in 2026Q1, indicating that the company continues to prioritize significant investment in its automated instrument base to secure long-term, high-margin consumable pull-through revenue across its global diagnostic and research segments.
The elevated capex levels appear to be a strategic choice to defend the company's installed base against competitors. While this spending is necessary to maintain the 'razor-blade' model, it effectively caps the near-term free cash flow available for shareholder returns or aggressive M&A activity.
As evidenced by recent filings, QIAGEN has shifted its capital deployment focus toward significant share repurchases, with $496.7 million utilized in 2026Q1 alone, which appears to be a deliberate effort to manage share count despite the simultaneous pressure on free cash flow generation and margin performance.
This level of buyback activity suggests management's confidence in the long-term value of the business, yet it may also indicate a lack of immediate, high-return acquisition targets. Investors should monitor whether this aggressive return of capital remains sustainable if free cash flow margins continue to face downward pressure.
Quick answers to the most common questions about buying QGEN stock.
Qiagen N.V. (QGEN) generated $654.3M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Qiagen N.V. (QGEN) generated $453.3M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Qiagen N.V. (QGEN) spent $207.1M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Qiagen N.V. (QGEN) returned $54.2M to shareholders via cash dividends and spent $307.4M on share repurchases. This shows the company's commitment to returning capital to its equity investors.